Quality Systems

Latest News


Report from India

As generic divisions become the most-wanted acquisitions of Big Pharma, India's domestic industry may be thinning out.

The Cold Shoulder

Reports of overlooked controls, dropped pallets, and misplaced documents leave a chill in the air.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Office of the Inspector General for the Department of Health and Human Services (HHS) issued a report, Challenges to FDA's Ability to Monitor and Inspect Foreign Clinical Trials, which evaluates the incidence of foreign clinical trials, the ability of the US Food and Drug Administration to oversee these trials, and recommendations to FDA on how to improve its oversight of foreign clinical trials.

Pharmaceutical Technology Europe

X-ray powder diffraction (XRPD) is a versatile, non-destructive technique that reveals detailed information about pharmaceuticals.

Pharmaceutical Technology Europe

With the increasing financial and technical means of counterfeiters, the number of counterfeit pharmaceuticals in the supply chain is growing at an alarming rate.

i1-675714-1408633098470.jpg

Pharmaceutical Technology Europe

We decided to dedicate this month's issue of PTE to a topic that affects all of our readers; the threat of counterfeit medicines.

Pharmaceutical Technology Europe

Teva Pharmaceuticals in the US has admitted to including false statements in the physician prescribing information for its oral contraceptive product Gianvi, a generic version of Bayer Healthcare?s YAZ oral contraceptive.

ePT--the Electronic Newsletter of Pharmaceutical Technology

A study conducted by the European Medicines Agency (EMA) has shown that statistical methods using EMA's EudraVigilance database of adverse drug reaction reports can be used to detect drug safety issues "significantly earlier" compared with routine pharmacovigilance.

ePT--the Electronic Newsletter of Pharmaceutical Technology

About one month after the announcement of McNeil Consumer Healthcare's recall of children's liquid pain and allergy medications , the US Food and Drug Administration testified before the US House Committee on Oversight and Government Reform about the issue.